breast cancer lung metastasisEGFRPI3k/AktEMTtherapeutic effectThe spreading of cancer cells from the primary tumor site to other parts of the body, known as metastasis, is the leading cause of cancer recurrence
Triple negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC) are amongst the most aggressive forms of solid tumors. TNBC is highlighted by absence of genetic components of progesterone receptor, HER2/neu and estrogen receptor in breast cancer. NSCLC is characterized by integration ...
Triple-negative breast cancer (TNBC) is highly aggressive, difficult to treat and commonly develops visceral metastasis, including lung metastasis. We observed that High mobility group box 1 protein (HMGB1) was highly expressed in human TNBC and positively correlated with cancer metastasis. The hypoxic...
Cancer disrupts intratumoral innate-adaptive immune crosstalk, but how the systemic immune landscape evolves during breast cancer progression remains unclear. We profiled circulating immune cells in stage I–III and stage IV triple-negative breast cancer (TNBC) patients and healthy donors (HDs). Metast...
TNBC, triple-negative breast cancer; BC, breast cancer; BCT, conservative surgery; CHT, chemotherapy; DFS, disease-free survival; LR, local relapse; DR, distant relapse; RT, radiotherapy; OS, overall survival; CMF, cyclophosphamide–methotrexate–5-fluorouracil; BLBC, basal-like breast cancer; PF...
Merck unveils data for Keytruda in triple-negative breast cancer, threatening Roche’s Tecentriq, but faces its own challenge from BMS in non-small cell lung cancer
Hemin sensitizes triple-negative breast cancer to metformin by degrading BACH1, a University of Chicago-led team has found. (nito100/iStock/Getty Images Plus) 而近日由芝加哥大学科学家团队通过细胞系和小鼠肿瘤模型的研究表明,将2种治疗糖尿病和卟啉症的药物-二甲双胍&血红素 -进行组合,可以抑制三阴性乳...
PD-1 blockade since PD-L1 is expressed on tumour cells while PD-1 is expressed on immune cells. However, not all PD-L1-expressing tumours respond to anti-PD-1/PD-L1 mAbs and it is noteworthy that some PD-L1-negative tumours such as PD-L1-negative lung cancer can respond to these ...
Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC) with a poor prognosis. Current treatment options are limited to surgery, adjuvant chemotherapy and radiotherapy; however, a proportion of patients have missed the surgical window at the time of diagnosis. TNBC...
breast cancer;triple negative breast cancer;proteomics;signaling pathway profiling;reverse phase protein array 1. Introduction Over the last few decades, we have witnessed substantial improvements in breast cancer (BC) mortality rates [1,2]; downward BC mortality trends are seen in most high-income ...